Compass Therapeutics reported a net loss of $25.2 million ($0.13 per share) for the quarter ended June 30, 2026, compared to $19.9 million in the prior year period. The company holds $180 million in cash and marketable securities, providing an anticipated runway into 2028. Pipeline updates include positive Phase 2/3 data for tovecimig in biliary tract cancer with an overall response rate of 18.0%, FDA feedback expected this quarter ahead of a potential BLA filing. Cohort expansions are enrolling for CTX-8371, while initial patients have been dosed in the Phase 1 study for CTX-10726 and a Phase 2 trial for CTX-471 is set to begin in Q3. Compass Therapeutics operates as a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics.